A method of treating pre-eclampsia and eclampsia

 

(57) Abstract:

The invention relates to medicine, namely to obstetrics, and can be used in the treatment of severe forms of preeclampsia and eclampsia. The patient through 7-48 h from the beginning of the ongoing standard therapy in addition enter dalargin in the amount of 1 mg When necessary, the introduction of dalargin repeat after 12-18 hours Method can improve the effectiveness of treatment and reduce mortality. 1 C.p. f-crystals.

The invention relates to medicine, namely to obstetrics, and can be used in the treatment of pre-eclampsia and eclampsia.

Toxaemia are the most common pathology of pregnancy. Over the last 5 years, the frequency of gestosis increased from 16 to 20% due to increase in pregnant extragenital pathology 1.7 - 2.8 times. Despite the close attention of obstetricians and gynecologists to the problem of gestosis, the decreasing tendency of this pathology is not observed among the causes of maternal mortality toxaemia take second place. Hence, an important task of modern obstetrics is to develop new methods of complex treatment of severe forms of preeclampsia and eclampsia.

The known method of lichenification, the membrane stabilizers and much more (A. P. silber, E. M. Shifman. Obstetrics eyes anesthesiologist. "Critical studies of medicine", so 3 - Petrozavodsk: Publisher PTU, 1997. - S. 397). However, this method does not guarantee the complete absence of stress alterius effects on homeostasis and therefore the effectiveness of the treatment is not high enough.

The aim of the invention is to increase the effectiveness of treatment of pre-eclampsia and eclampsia, reducing maternal mortality.

This objective is achieved in that on the background of standard therapy, the patient is injected bolus of 1 mg of dalargin intramuscularly or intravenously once or twice with an interval between injections 12-18 hours.

Comparative analysis of the prototype showed that the proposed method differs from the known fact that the patient is additionally administered dalargin for the proposed scheme.

Thus, the proposed solution meets the criteria of the invention of "novelty."

The analysis of patent literature showed that treatment of pre-eclampsia and eclampsia differs not only from the prototype, but also on other technical solutions in this and related fields. Birmingham in obstetric practice, namely, the proposed method allows to achieve this goal by reducing stress during the delivery of anesthesia and delivery.

This method can be used in obstetric hospitals in the treatment of pre-eclampsia and eclampsia by reducing stress during the delivery of anesthesia and delivery.

Thus, the proposed solution meets the criteria of "izobretatelsky level" and "industrial applicability".

The method is as follows: a woman arrives at the hospital in a state of severe pre-eclampsia. She start to standard therapy, including-blockers - atenolol-blockers - clonidine, calcium antagonists - verapamil, aldosterone antagonists - verospiron: peripheral antispasmodics - Dibazol with papaverine: sedative therapy - neuroleptics, magnesium therapy - membranostabilizatora, metabolic and antioxidant therapy. Through 7-48 h with treatment failure and when the decision on the mode of delivery type on a background of standard therapy 1 mg of dalargin intramuscularly or intravenously, if neobhodimoje to the hospital with complaints of headache, pain in the epigastric region, nausea, flashing flies" before the eyes, shortness of breath. Diagnosis: pregnancy 31-32 weeks, pre-eclampsia is severe, Mnogotochie. The condition is considered severe. At the time of inspection developed tonic-clonic seizures. HELL in the time of the attack 160/120 mm RT. Art. In connection with developed eclampsia started standard therapy antihypertensive therapy (atenolol, verospiron, cardizem, magnesium therapy, papaverine with Dibazol), metabolic therapy, antioxidants and membrane-protectors, sedative therapy - geksenal 1% - 300 mg intramuscularly and 150 mg intravenously. Attention was drawn to the makrogematuriya in combination with leukocyturia that was regarded as acute glomerulonephritis. Marked hypoproteinemia - 55 g/l, proteinuria - 3.3 g/l, an increase in serum transaminase (Alt - 3,4 and AST - 1,67). If treatment failure and the decision to deliver by caesarean section intramuscularly on the background of standard therapy and convulsive readiness once the bolus input dalargin 1 mg. Operation caesarean sections were performed under General anesthesia, diplegia, IVL. Hemodynamics during the whole operation was steady on figures 120/80 mm RT.art., predinsone patient was exuberan. During the next day was marked regression of neurological symptoms normalize the activity of serum transaminases, reducing the degree of proteinuria and hypertension. Two weeks later the patient was discharged in good condition.

Example 2. Patient B. 25 years (history of birth N 517) was admitted with a diagnosis: 24-26 weeks of pregnancy, childbirth, first, pre-eclampsia severe on the background of chronic pyelonephritis and diabetes. Started standard therapy. In connection with resistant arterial hypertension, constant, convulsive readiness urgently transaction caesarean section, in premedication included intravenous 1 mg of dalargin. After 3 h after extubation developed an attack of convulsions, a tendency to oliguria (10 ml/h), the patient was reintubation and transferred on a ventilator. In conditions of controlled hypotension in 7 hours re-entered 0,001 of dalargin intramuscularly. In a day when stabilization of hemodynamics, recovery of consciousness, hourly urine output of 50 ml/h) patient was exuberan. During the postpartum period without complications and on the ninth day the patient was discharged home. The child was in intensive care on a ventilator.

The proposed method was used in 76 b is s applied this method of treatment, there was a positive dynamics from both clinical, and laboratory parameters: namely noted stabilization of hemodynamics during surgery, reduced clinical manifestations dyscirculatory encephalopathy, occurs regression of neurological symptoms, reduction of proteinuria, normal activity of serum transaminase and so on, This method of treatment to prevent disruption of the mechanisms of adaptation of the system of autoregulation of vascular tone, homodynamic small circle of blood circulation, the blood coagulation system. All this allows you to prepare a woman for the gentle delivery tactics. The proposed method allowed us to avoid maternal mortality (for treatment by the method prototype maternal mortality in the same groups was 0.01%).

The advantages of this method enable to increase the effectiveness of treatment of pre-eclampsia and eclampsia, to avoid complications during anesthesia during surgery and childbirth by including in the complex therapy of neuropeptide of dalargin, to improve perinatal indicators.

1. A method of treating pre-eclampsia and eclampsia, including premedline enter dalargin in quantities of 1 mg.

2. The method according to p. 1, characterized in that the introduction of dalargin repeated after 12 - 18 o'clock

 

Same patents:

The invention relates to medical equipment, inhalation devices and methods of inhalation

The invention relates to medicine, namely to pharmacology, and relates to means for the treatment of inflammatory diseases of female genitals

The invention relates to the field of biotechnology

The invention relates to medicine, in particular to Infectology

The invention relates to a method for producing water-soluble conjugates (or their salts) polymyxin b B (PMB) or their salts and acid by the interaction of polymyxin b B or its salt with the acid in an aqueous medium at a pH of from about 9.3 to about 10, preferably from about 9.5 to about 9,7, and a temperature of from about 30oC to about 35oC, preferably about 32oC

The invention relates to novel antagonists of LH-RF, and above all, peptidomimetics and peptide with a modified side chain, of the formula V, where D-Xxx, R1- R8described in the description, and their salts with pharmaceutically acceptable acids, as well as it describes their therapeutic use as analogue releasing factor, luteinizing hormone (LH-RF) with high antagonistic activity and not detecting unwanted side effects, especially no incentive edema

The invention relates to medicine and relates to methods for obtaining protein hydrolysate suppressive regulation of allergic reactions, methods of prevention or treatment of allergies

The invention relates to medicine, in particular to Infectology
The invention relates to medicine, in particular to endocrinology and preventive medicine, and for the treatment of iodine deficiency in the body

The invention relates to veterinary medicine, namely to the means for prevention and treatment of gastrointestinal diseases calves
The invention relates to medicine and can be used in the treatment of diseases caused by disorders of the process of synthesis of collagen in humans, including arthritis, dermatitis and various forms of paradontosis

The invention relates to medicine and relates to pharmaceutical compositions for the treatment of cerebral disorders, to prevent the death of brain cells, induced by cerebral ischemia

The invention relates to the field of medicine and AIDS, normalizes metabolic processes in the cell
The invention relates to chemical-pharmaceutical industry, in particular the production of biologically active substances used to restore the protective vital functions of the human body
The invention relates to medicine, namely to neurosurgery, and can be used in the surgical treatment of ischemic brain
The invention relates to medicine and can be used to create artificial therapeutic mud

FIELD: biotechnology, biochemistry.

SUBSTANCE: invention relates to producing the biologically active complex eliciting antioxidant and immunomodulating activity and used in medicine, cosmetics, veterinary science and food industry. The biologically active complex preparing by enzymatic hydrolysis of muscle tissue represents complex of biologically active compounds involving carnosine and anserine in the amount 85-97 wt.-% of the native content of these components in poultry muscle tissue, 1-7 weight parts of amino acids, 0.5-12 weight parts of oligopeptides of molecular mass 10 kDa, not above, and 0.1-15 weight parts of cyclic and polycyclic phenolic compounds as measured for 1 weight part of carnosine and anserine in the complex. This complex is prepared by enzymatic hydrolysis of milled and homogenized water muscle tissue in preferable dilution homogenate with water in the range 0.2-0.6 and with using proteolytic enzymes in the amount 2-5 wt.-% of the protein content and working at pH 4.5-8.5 and at enhanced temperature being preferably at 45-65°C. Product is isolated as extract or powder prepared in drying the extract. Invention provides enhancing effectiveness of the claimed complex.

EFFECT: improved method for preparing, valuable properties of complex.

7 cl, 6 tbl, 6 ex

Up!